Average Metrics In A Turbulent Year: US FDA’s 2025 Median Review Times Match PDUFA Goals

 
• By Bridget Silverman
  
The FDA's review consistency provided valuable predictability to biopharma. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pink Sheet Perspectives

More from Pink Sheet